[63] A second trial, called Stalevo Reduction in Dyskinesia Evaluation (STRIDE-PD), was designed to evaluate whether Stalevo would delay the onset of dyskinesia compared with levodopa/carbidopa.

The FDA approved an oral extended-release formulation of levodopa and carbidopa known as IPX203 (Crexont) to treat Parkinson's disease, Amneal Pharmaceuticals announced Wednesday. The treatment is ...

In addition to the primary treatments for Parkinson’s disease, other medications can help manage specific symptoms, including: Carbidopa/levodopa is a combination medication that is sold under ...

While patients initially start taking oral drugs like levodopa and carbidopa to manage symptoms, these tend to lose their efficacy as the disease progresses and other therapies are added.

While patients with Parkinson’s initially start taking oral drugs like levodopa and carbidopa to manage symptoms, these often fail to control symptoms throughout a 24-hour period and tend to ...

The dopamine precursor levodopa is central to treatment for Parkinson's disease, but causes dyskinetic involuntary movements in many patients. Investigations carried out in Canada show that ...

In fluctuating Parkinson's disease (PD) patients, treatment of PD using the catechol-O-methyl transferase inhibitor entacapone with carbidopa/levodopa improves quality of life and activities of ...